Seminars in Oncology
Volume 30, Issue 3 , Pages 375-381 , June 2003

Post-treatment surveillance of patients with lymphoma treated with curative intent

  • James E. Wooldridge

      Affiliations

    • Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
    • *Address reprint requests to James E. Wooldridge, MD, Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52245 USA
    • ,
  • Brian K. Link

      Affiliations

    • Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Velasquez WS, McLaughlin P, Tucker S, et al.  ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol. 1994;12:1169–1176
  3. Yuen AR, Rosenberg SA, Hoppe RT, et al.  Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood. 1997;89:814–822
  4. Philip T, Guglielmi C, Hagenbeek A, et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545
  5. Armitage JO. The development of bone marrow transplantation as a treatment for patients with lymphoma—Twentieth Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1997;3:829–836
  6. Loprinzi CL, Hayes D, Smith T. Doc, shouldn’t we be getting some tests?. J Clin Oncol. 2000;18:2345–2348
  7. Weiss NS, Cook LS. Evaluating the efficacy of screening for recurrence of cancer. J Natl Cancer Inst. 1998;90:1870–1872
  8. Gallagher CJ, Gregory WM, Jones AE, et al.  Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol. 1986;4:1470–1480
  9. Peterson BA, Petroni GR, Frizzera G, et al.  Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: A study of the Cancer and Leukemia Group B. J Clin Oncol. 2003;21:5–15
  10. Miller TP, LeBlanc M, Grogan TM, et al.  Follicular lymphomas: Do histologic subtypes predict outcome?. Hematol Oncol Clin North Am. 1997;11:893–900
  11. Neubauer A, Thiede C, Morgner A, et al.  Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350–1355
  12. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–994
  13. Cheson BD, Horning SJ, Coiffier B, et al.  Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244
  14. Coiffier B, Gisselbrecht C, Herbrecht R, et al.  LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018–1026
  15. Surbone A, Longo DL, DeVita VT, et al.  Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: Significance and management. J Clin Oncol. 1988;6:1832–1837
  16. Radford JA, Cowan RA, Flanagan M, et al.  The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin’s disease. J Clin Oncol. 1988;6:940–946
  17. Young RC, Canellos GP, Chabner BA, et al.  Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer. 1978;42:1001–1007
  18. Yarnold JR, Jelliffe AM, Hudson GV. Patterns of relapse following radiotherapy for Hodgkin’s disease. Clin Radiol. 1982;33:137–140
  19. Russell KJ, Donaldson SS, Cox RS, et al.  Childhood Hodgkin’s disease: Patterns of relapse. J Clin Oncol. 1984;2:80–87
  20. Connors JM, Noordijk EM, Horning SJ. Hodgkin’s lymphoma: Basing the treatment on the evidence. Hematology (Am Soc Hematol Educ Program). 2001;178–193
  21. Radford JA, Eardley A, Woodman C, et al.  Follow up policy after treatment for Hodgkin’s disease: Too many clinic visits and routine tests?A review of hospital records. BMJ. 1997;314:343–346
  22. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin’s disease: Role of routine follow-up studies. J Clin Oncol. 1997;15:1123–1130
  23. Gordon LI, Harrington D, Andersen J, et al.  Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin’s lymphoma. N Engl J Med. 1992;327:1342–1349
  24. Fisher RI, Gaynor ER, Dahlberg S, et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  25. Shipp MA, Klatt MM, Yeap B, et al.  Patterns of relapse in large-cell lymphoma patients with bulk disease: Implications for the use of adjuvant radiation therapy. J Clin Oncol. 1989;7:613–618
  26. Weeks JC, Yeap BY, Canellos GP, et al.  Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196–1203
  27. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes.Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795
  28. Elis A, Blickstein D, Klein O, et al.  Detection of relapse in non-Hodgkin’s lymphoma: Role of routine follow-up studies. Am J Hematol. 2002;69:41–44
  29. Boger-Megiddo I, Apter S, Spencer JA, et al.  Is chest CT sufficient for follow-up of primary mediastinal B-cell lymphoma in remission?. AJR Am J Roentgenol. 2002;178:165–167
  30. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears?. Eur J Nucl Med. 2000;27:1564–1578
  31. Naumann R, Vaic A, Beuthien-Baumann B, et al.  Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol. 2001;115:793–800
  32. Weyburn TD, Wiseman GA, Link BK, et al.  FDG-PET predicts the one year progression-free survival (1-y PFS) of patients with diffuse large B-cell lymphoma following anthracycline-based chemotherapy. Blood. 2002;100(suppl 1):768a; abstr
  33. Dores GM, Metayer C, Curtis RE, et al.  Second malignant neoplasms among long-term survivors of Hodgkin’s disease: A population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494
  34. Sklar C, Whitton J, Mertens A, et al.  Abnormalities of the thyroid in survivors of Hodgkin’s disease: Data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–3232
  35. Ding SH, Pledge SD, Harrison BJ, et al.  The incidence of thyroid abnormalities in adults irradiated for lymphoma. Int J Oncol. 2002;20:1065–1069
  36. Edelman MJ, Meyers FJ, Siegel D. The utility of follow-up testing after curative cancer therapy: A critical review and economic analysis. J Gen Intern Med. 1997;12:318–331
  37. Gustavsson A, Eskilsson J, Landberg T, et al.  Late cardiac effects after mantle radiotherapy in patients with Hodgkin’s disease. Ann Oncol. 1990;1:355–363
  38. Hubbard SM, Longo DL. Treatment-related morbidity in patients with lymphoma. Curr Opin Oncol. 1991;3:852–862
  39. Glanzmann C, Kaufmann P, Jenni R, et al.  Cardiac risk after mediastinal irradiation for Hodgkin’s disease. Radiother Oncol. 1998;46:51–62
  40. Velasquez WS, Cabanillas F, Salvador P, et al.  Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117–122
  41. Armitage JO. Bone marrow transplantation in the treatment of patients with lymphoma. Blood. 1989;73:1749–1758
  42. Sureda A, Arranz R, Iriondo A, et al.  Autologous stem-cell transplantation for Hodgkin’s disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol. 2001;19:1395–1404
  43. Caballero MD, Perez-Simon JA, Iriondo A, et al.  High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol. 2003;14:140–151
  44. Fields PA, Goldstone AH. Non-Hodgkin’s lymphomas: Clinical governance issues. Best Pract Res Clin Haematol. 2002;15:577–596

PII: S0093-7754(03)00096-4

Seminars in Oncology
Volume 30, Issue 3 , Pages 375-381 , June 2003

Article Tools